SCHEMBL12876559

SCHEMBL12876559

Cc1cccc(-c2cc(Br)c(C)s2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B1 P14061 6/20 0.42
HSD17B2 P37059 6/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ACHE P22303 1/20 0.39
TSHR P16473 3/20 0.39
NPSR1 Q6W5P4 2/20 0.39
NISCH Q9Y2I1 1/20 0.38
CHRNB4 P30926 1/20 0.38
CHRNA3 P32297 1/20 0.38
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
RAB9A P51151 2/20 0.37
MAP3K8 P41279 1/20 0.36
CNR1 P21554 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6812091 0.86 MAPT (0.40) ALDH1A1MAPK1HSD17B1HSD17B2MEN1
SCHEMBL28848007 0.82 ESR1 (0.43) ALDH1A1HSD17B1HSD17B2MEN1KMT2A
SCHEMBL17066346 0.81 HSD17B1 (0.47) ALDH1A1HSD17B1HSD17B2MEN1KMT2A
SCHEMBL1198680 0.80 HDAC6 (0.44) ALDH1A1MEN1KMT2ANPSR1HPGD
SCHEMBL27811389 0.79 NPC1 (0.42) ALDH1A1MAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL19741486 0.76 HSD17B1 (0.56) ALDH1A1HSD17B1HSD17B2MEN1KMT2A
SCHEMBL28530288 0.76 SNCA (0.50) ALDH1A1MAPK1HSD17B1HSD17B2MEN1
SCHEMBL9034233 0.76 GSK3B (0.45) TSHRLMNARAB9ANPC1HDAC4
SCHEMBL27797494 0.76 IKBKB (0.40) ALDH1A1HSD17B1HSD17B2MEN1KMT2A
SCHEMBL17376763 0.75 CYP2A6 (0.47) ALDH1A1HPGDSMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885MAPK1 255/4885HSD17B1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.